Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Last Close
Oct 04 04:00PM ET
6.63
Dollar change
+0.13
Percentage change
2.00
%
Index- P/E- EPS (ttm)-5.36 Insider Own63.38% Shs Outstand23.20M Perf Week9.59%
Market Cap293.18M Forward P/E- EPS next Y-1.72 Insider Trans-0.15% Shs Float16.19M Perf Month1.53%
Income-130.43M PEG- EPS next Q-0.41 Inst Own35.78% Short Float1.34% Perf Quarter-26.33%
Sales0.00M P/S- EPS this Y98.95% Inst Trans11.13% Short Ratio1.11 Perf Half Y-59.74%
Book/sh5.21 P/B1.27 EPS next Y-11.95% ROA-94.04% Short Interest0.22M Perf Year-39.51%
Cash/sh5.83 P/C1.14 EPS next 5Y- ROE-103.02% 52W Range4.42 - 47.17 Perf YTD-28.17%
Dividend Est.- P/FCF- EPS past 5Y- ROI-51.47% 52W High-85.94% Beta-0.67
Dividend TTM- Quick Ratio19.52 Sales past 5Y0.00% Gross Margin- 52W Low50.00% ATR (14)0.84
Dividend Ex-DateAug 03, 2015 Current Ratio19.52 EPS Y/Y TTM-103111.54% Oper. Margin0.00% RSI (14)50.32 Volatility9.80% 13.96%
Employees33 Debt/Eq0.11 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price30.17
Option/ShortNo / Yes LT Debt/Eq0.10 EPS Q/Q-544.47% Payout- Rel Volume0.55 Prev Close6.50
Sales Surprise- EPS Surprise14.73% Sales Q/Q- EarningsSep 10 AMC Avg Volume195.11K Price6.63
SMA200.78% SMA50-3.38% SMA200-37.38% Trades Volume106,839 Change2.00%
Date Action Analyst Rating Change Price Target Change
Aug-28-24Initiated Oppenheimer Outperform $30
Apr-22-24Initiated Wells Fargo Overweight $30
Apr-15-24Initiated Guggenheim Buy $34
Mar-28-24Initiated UBS Buy $37
Mar-08-24Initiated Morgan Stanley Overweight $40
Feb-20-24Initiated Leerink Partners Outperform $31
Oct-01-24 04:05PM
Sep-26-24 06:30AM
Sep-14-24 10:08PM
Sep-10-24 04:33PM
Aug-28-24 04:05PM
04:05PM Loading…
Jul-24-24 04:05PM
06:30AM
Jul-18-24 08:00AM
Jun-14-24 07:01AM
May-29-24 07:30AM
May-15-24 04:05PM
May-02-24 04:05PM
Apr-09-24 08:56AM
08:00AM
Mar-11-24 05:16PM
07:00AM Loading…
Mar-05-24 07:00AM
Feb-14-24 06:50AM
06:45AM
Jan-30-24 07:00AM
Jan-29-24 07:00AM
Dec-22-23 05:00PM
Dec-19-23 07:00AM
Nov-29-23 07:00AM
Nov-13-23 09:55AM
Nov-02-23 07:00AM
Nov-01-23 07:30AM
enGene Holdings, Inc. is a clinical-stage biotechnology company, which engages in developing gene therapies. It is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs. The company was founded by Anthony T. Cheung on April 24, 2023 and is headquartered in Saint-Laurent, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cooper Ronald Harold WilfredChief Executive OfficerSep 27 '24Buy5.7010,00057,00010,000Oct 01 08:02 AM
Glickman Richard MDirectorMay 28 '24Option Exercise0.8912010724,675May 29 06:12 PM
FONDS DE SOLIDARITE DES TRAVAI10% OwnerApr 22 '24Sale15.0047,854717,8103,036,153Apr 22 05:22 PM
FONDS DE SOLIDARITE DES TRAVAI10% OwnerApr 18 '24Sale15.014,57568,6713,084,107Apr 22 05:22 PM
FONDS DE SOLIDARITE DES TRAVAI10% OwnerApr 19 '24Sale15.001001,5003,084,007Apr 22 05:22 PM
CHEUNG ANTHONY TZEYEWChief Technology OfficerMar 18 '24Option Exercise0.8952,94047,117102,873Mar 20 04:42 PM